Результаты поиска

Pharmacological interventions for hypertension in children.

BACKGROUND: Hypertension is a major risk factor for stroke, coronary artery disease and kidney damage in adults. There is a paucity of data … and diastolic blood pressure by 5.50 mmHg (95% CI -9.62 to -1.38) (low-quality evidence). High dose telmisartan (one trial, n = 76), when compared to placebo, reduced systolic blood pressure by -8.50 (95% CI -13.79 to -3.21) but not diastolic blood pressure (-4.80, 95% CI -9.50 to 0.10) (low-quality evidence). Beta blocker (metoprolol, one trial, n = 140), wh …

Cochrane in context: pharmacological interventions for hypertension in children.

BACKGROUND: Hypertension is a major risk factor for stroke, coronary artery disease and kidney damage in adults. There is a paucity of data … od pressure by 5.50 mmHg (95% confidence interval .9.62 to .1.38) (low-quality evidence). High dose telmisartan (one trial, n=76), when compared with placebo, reduced systolic blood pressure by .8.50 (95% confidence interval .13.79 to .3.21) but not diastolic blood pressure (.4.80, 95% . .9.50 to 0.10) (low-quality evidence). ..-Blocker (metoprolol, one trial …

CONGRESS REPORT OF THE 5TH NATIONAL CONGRESS OF THE BULGARIAN SOCIETY FOR DERMATOLOGIC SURGERY, SOFIA, 11TH MARCH 2023 WITH MAIN TOPICS: NITROSAMINES AS MOST POWERFUL TRIGGER FOR SKIN CANCER DEVELOPMENT AND PROGRESSION/PERSONALISED ONE STEP MELANOMA SURGERY AS POSSIBLE SKIN CANCER TREATMENT OPTION.

Deciphering the mutational pattern of skin tumours, remains a major challenge for clinicians and researchers. Over 80% of mutations in tumou … cines worldwide: metformin, ranitidine, propranolol, rifampicin, irbesartan, olmesartan, valsartan, telmisartan, eprosartan, losartan, ACE inhibitors, thiazide diuretics, etc. In certain geographical regions, there is almost no patient taking this type of medication who has not had at least one tumour detected. These significant correlations (nitrosamines/can …

Renin inhibitors versus angiotensin receptor blockers for primary hypertension.

BACKGROUND: Renin inhibitors, which inhibit the first and rate-limiting step in the renin angiotensin system (RAS), are thought to be more e … comparator was losartan in four trials, valsartan in three trials, irbesartan in three trials, and telmisartan in one trial. There were very limited or no data on cardiovascular outcomes and ESRD. There may be little to no difference between renin inhibitors and ARBs in all-cause mortality (RR 0.35, 95% CI 0.07 to 1.64; 3 studies, 1932 participants; low-cert …

Pharmacological interventions for hypertension in children.

BACKGROUND: Hypertension is a major risk factor for stroke, coronary artery disease and kidney damage in adults. There is a paucity of data … and diastolic blood pressure by 5.50 mmHg (95% CI -9.62 to -1.38) (low-quality evidence). High dose telmisartan (one trial, n = 76), when compared to placebo, reduced systolic blood pressure by -8.50 (95% CI -13.79 to -3.21) but not diastolic blood pressure (-4.80, 95% CI -9.50 to 0.10) (low-quality evidence). Beta blocker (metoprolol, one trial, n = 140), wh …

(NDMA) METFORMIN AND (NTTP) SITAGLIPTIN INDUCED CUTANEOUS MELANOMAS: LINKS TO NITROSOGENESIS, NITROSO-PHOTOCARCINOGENESIS, ONCOPHARMACOGENESIS AND THE METABOLIC REPROGRAMMING.

Changing the vision, understanding, interpretation and analysis of certain data or scientific dilemmas is what is able to change the status … ter combined intake (or monomedication) of/ between ranitidine, valsartan, olmesartan, candesartan, telmisartan, irbesartan, losartan, enalapril, lisinopril, perindopril, hydrochlorothiazide, nifedipine, amlodipine, propafenone, bisoprolol, nebivolol, melitracen and a number of others, we inform about another rare but not unexpected clinical observation: occu …

2018 ACVIM Forum Research Report Program. Seattle, Washington, June 14 - 16, 2018.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Repositioning of drugs for Parkinson's disease and pharmaceutical nanotechnology tools for their optimization.

Parkinson's disease (PD) significantly affects patients' quality of life and represents a high economic burden for health systems. Given the lack of safe and effective treatments for PD, drug repositioning seeks to offer new medication alternatives, reducing research time and costs compared to the traditional drug development strategy. This review aimed to collect evidence of drugs proposed as candidates to be reused in PD and identify those with the potential to be reformulated into nanocarriers to optimize future repositioning trials. We conducted a detailed search in PubMed, Web of Science,

Совпадение в полном тексте источника
… Subgroup B1 (n = 28) was treated with vehicle, subgroup B2 (n = 24) with candesartan, and subgroup B3 (n = 24) with telmisartan | [ 62 ] Telmisartan | Hypertension | AT1 receptor antagonist. … Reformulation in NPs could improve oral bioavailability and target the brain Telmisartan | N/I | Yes (dose-dependent) | Polymeric NPs/PLA [ 138 ] | Low oral bioavailability, poor solubility. …

Targetable pathways for drug repurposing in gastric cancer.

Gastric cancer (GC) is both the fifth most common cancer worldwide and the fifth in mortality. Owing to a lack of symptoms in the early stages and unspecific clinical presentation in the later stages, GC is usually diagnosed at advanced stages. This means that only approximately 60% of patients are eligible for curative treatment, and overall, GC patients have a 5-year survival rate of only 28.3%, underscoring the importance of developing new treatment strategies. Drug repurposing involves identifying new therapeutic uses for approved drugs and is a promising strategy for cancer treatment beca

Совпадение в полном тексте источника
… and activate tumorigenic pathways | Panneerpandian et al [ 102 ] Candesartan | Angiotensin II type I receptor blocker | Hypertension, heart failure, diabetic neuropathy | TGF-β1 | Suppress tumor cell proliferation and stromal fibrosis in xenograph models | Araújo et al [ 29 ]; Okazaki et al [ 103 ] Telmisartan … Another angiotensin receptor blocker is telmisartan, which is used for the same purposes as candesartan[ 29 ]. Telmisartan has been shown to be effective against a variety of cancers, including T-cell leukemia, esophageal adenocarcinoma, and hepatocellular carcinoma. …

Therapeutic strategies against cancer cachexia.

Cancer cachexia has two main components: anorexia and metabolic alterations. The main changes associated with the development of this multi-organic syndrome are glucose intolerance, fat depletion and muscle protein hypercatabolism. The aim of this paper is to review the more recent therapeutic approaches designed to counteract the wasting suffered by the cancer patient with cachexia. Among the most promising approaches we can include the use of ghrelin agonists, beta-blockers, beta-adrenergic agonists, androgen receptor agonists and anti-myostatin peptides. The multi-targeted approach seems es

Совпадение в полном тексте источника
… Thus, one of this compounds, Telmisartan, can be used as an add-on therapy with 5-fluorouracil, 47 or cisplatin, 48 or other traditional chemotherapeutic agents. … Evaluation of role of telmisartan in combination with 5-fluorouracil in gastric cancer cachexia. Life Sci 2016;154:15-23. 48. Patel BM, Damle D. Combination of Telmisartan with Cisplatin Controls Oral Cancer Cachexia in Rats. Biomed Res Int 2013;2013:1-10. 49. …

Impact of lanadelumab in hereditary angioedema: a case series of 12 patients in Canada.

BackgroundHereditary angioedema (HAE) is a rare autosomal dominant disease resulting in recurring episodes of swelling, leading to considerable patient morbidity and mortality. Lanadelumab is a plasma kallikrein inhibitor that is approved as 1st line therapy in Canada for long term prophylaxis of HAE attacks.ObjectiveTo describe our clinical findings from a case series of adult patients with HAE type 1/2 who have been initiated on lanadelumab.MethodsA chart review of HAE type 1/2 patients at three academic centers in Canada was undertaken with demographic and clinical data extracted. Patients

Совпадение в полном тексте источника
… 1 Nil Nil 18 18 2 24 M 1 Nil Nil 1 4 3 42 F 1 SLE (quiescent) Nil 10 23 4 38 F 2 Nil Nil 11 2 5 36 F 1 Ulcerative Colitis Nil 4 12 6 30 F 1 GERD, Chronic Pain Methadone 23 25 7 59 F 1 Nil Nil 26 59 8 34 F 1 Depression Citalopram 11 11 9 50 F 1 Nil Nil 47 48 10 74 F 1 Multiple Myeloma, HTN Revlimid, Telmisartan … Nil | 11 | 2 5 | 36 | F | 1 | Ulcerative Colitis | Nil | 4 | 12 6 | 30 | F | 1 | GERD, Chronic Pain | Methadone | 23 | 25 7 | 59 | F | 1 | Nil | Nil | 26 | 59 8 | 34 | F | 1 | Depression | Citalopram | 11 | 11 9 | 50 | F | 1 | Nil | Nil | 47 | 48 10 | 74 | F | 1 | Multiple Myeloma, HTN | Revlimid, Telmisartan …

Drug Repurposing for the Management of Depression: Where Do We Stand Currently?

A slow rate of new drug discovery and higher costs of new drug development attracted the attention of scientists and physicians for the repurposing and repositioning of old medications. Experimental studies and off-label use of drugs have helped drive data for further studies of approving these medications. A deeper understanding of the pathogenesis of depression encourages novel discoveries through drug repurposing and drug repositioning to treat depression. In addition to reducing neurotransmitters like epinephrine and serotonin, other mechanisms such as inflammation, insufficient blood supp

Совпадение в полном тексте источника
… | NA Valproic acid | Retrospective clinical analysis (PM surveillances and CD) [ 13 ] | Resistant depression (SA) [ 13 ] Zinc | Retrospective clinical analysis (PM surveillances and CD) [ 21 ] | MDD (INV) [ 46 ] Pramipexole | Retrospective clinical analysis (EHRs) [ 21 ] | MDD (SA, INV) [ 21 , 47 ] Telmisartan … The results of observational or case-control studies indicated a lower risk of MDD in patients using angiotensin-converting enzyme inhibitors (ACEIs) like telmisartan in comparison with other antihypertensive medications. …

Nephrology in Veterinary Medicine.

Veterinary nephrology is a specialized field of veterinary medicine providing a high level of care for animals with all types of kidney disease. Veterinarians complete extensive training to become board-certified in veterinary nephrology-urology. Companion animal nephrology is the most advanced field; however, all species are afflicted by a variety of renal disorders. Most naturally occurring animal kidney diseases have similar disorders found in people; where veterinary research is lacking, clinical management is often modified from standard of care in people. Veterinarians have become adept

Совпадение в полном тексте источника
… Telmisartan was also administered at 1.3 mg/kg by mouth every 24h. Recheck lab work performed 1 month later and found resolution of the azotemia (serum creatinine 1.5 mg/dl, BUN 22 mg/dl) and hyperphosphatemia (4.3 mg/dl). … Mycophenolate was discontinued after an additional 6 months of treatment, and telmisartan was continued. The patient has not demonstrated further relapse and continues to be nonazotemic and minimally proteinuric up to the time of manuscript submission (6 years later). …

Recent Perspectives on Cardiovascular Toxicity Associated with Colorectal Cancer Drug Therapy.

Cardiotoxicity is a well-known adverse effect of cancer-related therapy that has a significant influence on patient outcomes and quality of life. The use of antineoplastic drugs to treat colorectal cancers (CRCs) is associated with a number of undesirable side effects including cardiac complications. For both sexes, CRC ranks second and accounts for four out of every ten cancer deaths. According to the reports, almost 39% of patients with colorectal cancer who underwent first-line chemotherapy suffered cardiovascular impairment. Although 5-fluorouracil is still the backbone of chemotherapy reg

Совпадение в полном тексте источника
… Twenty-five individuals who started taking telmisartan one week prior to chemotherapy were examined using a tissue Doppler echo technique. … These findings imply that telmisartan may offer protection against ROS production brought on by epirubicin and may suppress the growth of inflammation, delaying the onset of cardiac damage [ 91 ]. …

Cardiotoxicity after cancer treatment: a process map of the patient treatment journey.

Background/aimCardiotoxicity is a potential complication of anticancer therapy. While guidelines have been developed to assist practitioners, an effective, evidence based clinical pathway for the treatment of cardiotoxicity has not yet been developed. The aim of this study was to describe the journey of patients who developed cardiotoxicity through the healthcare system in order to establish baseline data to inform the development and implementation of a patient-centred, evidence-based clinical pathway.MethodsMixed-methods design with quantitative and qualitative components using process mappi

Совпадение в полном тексте источника
… amiodarone, amlodipine, atenolol, atorvastatin, bisoprolol, candesartan, carvedilol, cephalexin, cholecalciferol, clonidine, clopidogrel, digoxin, diltiazem, enalapril, enoxaparin, eprosartan, exemestane, frusemide, ibandronate, irbesartan, itraconazole, ivabradine, letrozole, lisinopril, metoprolol, telmisartan … amiodarone, amlodipine, atenolol, atorvastatin, bisoprolol, candesartan, carvedilol, cephalexin, cholecalciferol, clonidine, clopidogrel, digoxin, diltiazem, enalapril, enoxaparin, eprosartan, exemestane, frusemide, ibandronate, irbesartan, itraconazole, ivabradine, letrozole, lisinopril, metoprolol, telmisartan …

Oxidized Lipids in Persistent Pain States.

Chemotherapy, nerve injuries, or diseases like multiple sclerosis can cause pathophysiological processes of persistent and neuropathic pain. Thereby, the activation threshold of ion channels is reduced in peripheral sensory neurons to normally noxious stimuli like heat, cold, acid, or mechanical due to sensitization processes. This leads to enhanced neuronal activity, which can result in mechanical allodynia, cold allodynia, thermal hyperalgesia, spontaneous pain, and may initiate persistent and neuropathic pain. The treatment options for persistent and neuropathic pain patients are limited; f

Совпадение в полном тексте источника
… Administration of the CYP2J2 inhibitor Telmisartan was sufficient to reduce neuronal synthesis of CYP2J2 derived oxidized lipids and to reduce mechanical hypersensitivity of mice during paclitaxel-induced neuropathic pain in a dose-dependent and preventive manner ( Sisignano et al., 2016 ) ( Figure 2 … Telmisartan can be easily repurposed as CYP2J2 inhibitor due to long clinical experience with this drug and its good tolerability in patients ( Battershill and Scott, 2006 ), whereas the unselective antifungal CYP-inhibitor ketoconazole is not suitable for systemic use due to high cross-reactivity, and …

Association Between Interleukin-6 and Head and Neck Squamous Cell Carcinoma: A Systematic Review.

Interleukin-6 (IL-6) is a proinflammatory cytokine which plays an important role in several regulatory mechanisms of cancer. Moreover, experimental and clinical studies have reported that IL-6 targeted therapies might provide significant benefits for cancer treatment. The purpose of this systematic review is to evaluate IL-6 activity in patients with head and neck squamous cell carcinoma (HNSCC). A systematic review of the association between serum, saliva and tumor IL-6 and HNSCC was developed on PubMed/Medline in the publication range from January 1995 to January 2019. Our literature analysi

Совпадение в полном тексте источника
… In an experimental oral cancer model, a specific angiotensin II receptor blocker (Telmisartan; Micardis, Boehringer Ingelheim, Ingelheim am Rhein, Germany), which also inhibits IL-6 expression, controlled cancer cachexia successfully when used in combination with cisplatin [ 68 ]. … Garrett IR Mundy GR Chinese hamster ovarian cells transfected with the murine interleukin-6 gene cause hypercalcemia as well as cachexia, leukocytosis and thrombocytosis in tumor-bearing nude mice Endocrinology 1991 5 128 5 2657 9 2019273 10.1210/endo-128-5-2657 68 Patel BM Damle D Combination of telmisartan …

RESEARCH COMMUNICATIONS OF THE 28th ECVIM-CA CONGRESS.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… of Veterinary Endocrinology Friday 7 September 2018 14.25‐14.40 | ESVE‐O‐1 | Peterson | Radioiodine treatment of feline hyperthyroidism: measuring 24‐hour thyroid 131‐I uptake helps predict treatment failure or development of iatrogenic hypothyroidism 14.40‐14.55 | ESVE‐O‐2 | Fabres | Evaluation of telmisartan … with spontaneous hypothyroidism ESVE‐P‐13 | Malerba | Accuracy of a flash glucose monitoring system in dogs with diabetic ketoacidosis ESVE‐P‐14 | Rapastella | Predictors of response to pituitary radiotherapy in dogs with and without pituitary dependent hyperadrenocorticism ESVE‐P‐15 | Gónzalez Sanz | Telmisartan …

Mechanisms to medicines: navigating drug repurposing strategies in Alzheimer's disease.

Alzheimer's disease (AD) represents a continuously advancing neurodegenerative condition distinguished by the unremitting deterioration of cognitive abilities and memory impairment, which significantly hampers daily functioning of life. In the absence of disease modifying treatments, it continues to pose a significant global challenge. Though symptomatic treatment exists, the inherent complexity involved with AD pathogenesis related to Aβ plaques, neurofibrillary tangles, neuroinflammation, oxidative stress, etc. poses a tremendous challenge to developing drugs. With the incidence of AD increa

Совпадение в полном тексте источника
… Section B lists antagonists: Memantine, Telmisartan, Suvorexant. Section C lists agonists: Bexarotene, Tamibarotene. TABLE 1 Detailed overview of the inhibitors targeting Alzheimer’s disease: current therapeutic regime. … Overdose: ECG change, bradycardia, increased blood pressure, stupor, psychosis, vomiting | - | Moderate to severe AD (FDA approved 2003) | Approved | ( Kishi et al., 2017 ; Matsunaga et al., 2018 ; Balázs et al., 2021 ; Tang et al., 2023 ; Singh and Kumar, 2024 ) 2. | Angiotensin II Receptor Antagonist | Telmisartan …

Cancer-Therapy-Related Cardiac Dysfunction: Latest Advances in Prevention and Treatment.

The increasing efficacy of cancer therapies has significantly improved survival rates, but it has also highlighted the prevalence of cancer-therapy-related cardiac dysfunction (CTRCD). This review provides a comprehensive overview of the identification, monitoring, and management of CTRCD, a condition resulting from several treatments, such as anthracyclines, HER2-targeted therapies, target therapies, and radiotherapy. The paper includes a discussion of the mechanisms of CTRCD associated with various cancer treatments. Early detection through serum biomarkers and advanced imaging techniques is

Совпадение в полном тексте источника
… Cadeddu et al. studied telmisartan (40 mg/day) in 49 epirubicin-treated patients, administered 1 week before and throughout chemotherapy. While LVEF remained unchanged, telmisartan prevented LV diastolic dysfunction, as shown by preservation of the early/late diastolic peak velocity (E/A) ratio. … Additionally, telmisartan reduced ROS and IL-6, suggesting anti-inflammatory and antioxidant benefits. Despite these findings, the small sample size and short follow-up limited the study’s broader applicability [ 86 , 87 ]. …